Library · Oncology, infection & imaging
Gadopiclenol
Elucirem, Vueway
Macrocyclic gadolinium-based MRI contrast agent approved in September 2022, engineered with a hydration number of 2 for two-to-three times greater relaxivity than standard agents. Allows use at half the usual dose while maintaining diagnostic quality, cutting gadolinium exposure.
Research score 85/100. Reference only, not a dose.
- Diagnostic Imaging
- Contrast Enhancement
- US status
- Prescription Only - Diagnostic
- Approval
- FDA Approved (2022)
- Evidence
- PICTURE trial: non-inferior to gadobutrol at half the gadolinium dose
- Research score
- 85 / 100
- Indication
- MRI contrast agent for CNS and body imaging
- Origin
- United States
- Source category
- Diagnostic & Imaging
- Status group
- Approved / prescription
Mechanism
Its macrocyclic structure lets gadolinium interact with twice the water molecules of standard agents, boosting relaxivity and tissue signal enhancement at a lower dose.
Safety file
Well tolerated, with a safety profile similar to other macrocyclic gadolinium agents.
- Typical for gadolinium contrast agents - minimal